Current Status of Ribozymes as Gene Therapy Agents for Cancer

REFERENCES

• Cech T. R., Zaug A. J., Grabowski P. J. In Vitro Splicing of the Ribosomal RNA Precursor of Tetrahymena: Involvement of a Guanosine Nucleotide in the Excision of the Intervening Sequence. Cell 1981; 22: 487–496
   Google Scholar
• Castanotto D., Rossi J. J., Deshler J. O. Biological and Functional Aspects of Catalytic RNAs. Crit. Rev. Eukaryot. Gene Expr 1992; 2: 331–357
   PubMedGoogle Scholar
• Cech T. R. The Chemistry of Self-Splicing RNA and RNA Enzymes. Science 1987; 236: 1532–1539
   PubMed Web of Science ®Google Scholar
• Forster A. C., Symons R. H. Self-Cleavage of Plus and Minus RNAs of a Virusoid and a Structural Model for the Active Sites. Cell 1987; 49: 211–220
   PubMed Web of Science ®Google Scholar
• Haseloff J., Gerlach W. L. Simple RNA Enzymes with New and Highly Specific Endoribonuclease Activities. Nature 1988; 334: 585–591
   PubMed Web of Science ®Google Scholar
• Ruffner D. E., Stormo G. D., Uhlenbeck O. C. Sequence Requirements of the Hammerhead RNA Self- Cleavage Reaction. Biochemistry 1990; 29: 10695–10702
   PubMed Web of Science ®Google Scholar
• Perriman R., Delves A., Gerlach W. L. Extended Target- Site Specificity for a Hammerhead Ribozyme. Gene 1992; 113: 157–163
   PubMed Web of Science ®Google Scholar
• Shimayama T., Nishikawa S., Taira K. Generality of the NUX Rule: Kinetic Analysis of the Results of Systematic Mutations in the Trinucleotide at the Cleavage Site of Hammerhead Ribozymes. Biochemistry 1995; 34: 3649–3654
   PubMed Web of Science ®Google Scholar
• Zoumadakis M., Tabler M. Comparative Analysis of Cleavage Rates After Systematic Permutation of the NUX Consensus Target Motif for Hammerhead Ribozymes. Nucleic Acids Res 1995; 23: 1192–1196
   PubMed Web of Science ®Google Scholar
• Dahm S. C., Uhlenbeck O. C. Role of Divalent Metal Ions in the Hammerhead RNA Cleavage Reaction. Biochemistry 1991; 30: 9464–9469
   PubMed Web of Science ®Google Scholar
• Uebayasi M., Uchimaru T., Koguma T., et al. Theoretical and Experimental Considerations on the Hammerhead Ribozyme Reactions: Divalent Magnesium Ion Mediated Cleavage of Phosphorus-Oxygen Bonds. J. Org. Chem 1994; 59: 7414–7420
   Web of Science ®Google Scholar
• Sawata S., Komiyama M., Taira K. Kinetic Evidence Based on Solvent Isotope Effects for the Nonexistence of a Proton-Transfer Process in Reactions Catalysed by a Hammerhead Ribozyme: Implication to the Double- Metal-Ion Mechanism of Catalysis. J. Am. Chem. Soc. 1995; 117: 2357–2358
   Web of Science ®Google Scholar
• Pontius B. W., Lott W. B., von Hippel P. H. Observations on Catalysis by Hammerhead Ribozymes Are Consistent with a Two-Metal-Ion Mechanism. Proc. Natl. Acad. Sci. U.S.A. 1997; 94: 2290–2294
   PubMed Web of Science ®Google Scholar
• Lott W. B., Pontius B. W., von Hippel P. H. A Two- Metal Ion Mechanism Operates in the Hammerhead Ribozyme- Mediated Cleavage of an RNA Substrate. Proc. Natl. Acad. Sci. U.S.A. 1998; 95: 542–547
   PubMed Web of Science ®Google Scholar
• Long D. M., Uhlenbeck O. C. Self-Cleaving Catalytic RNA. FASEB J. 1993; 7: 25–30
   PubMed Web of Science ®Google Scholar
• Hampel A., Tritz R. RNA Catalytic Properties of the Minimum (–)sTRSV Sequence. Biochemistry 1989; 28: 4929–4933
   PubMed Web of Science ®Google Scholar
• Herschlag D., Cech T. R. Catalysis of RNA Cleavage by the Tetrahymena thermophilia Ribozyme. 1. Kinetic Description of the Reaction of an RNA Substrate Complementary to the Active Site. Biochemistry 1990; 29: 10159–10171
   PubMed Web of Science ®Google Scholar
• Zamecnik P. C., Stephenson M. L. Inhibition of Rous sarcoma Virus Replication and Cell Transformation by 506 Wright and Kearney a Specific Oligodeoxynucleotide. Proc. Natl. Acad. Sci. U.S.A. 1978; 75: 280–284
   PubMed Web of Science ®Google Scholar
• McManaway M. E., Neckers L. M., Loke S. L. et. al. Tumour-Specific Inhibition of Lymphoma Growth by an Antisense Oligodeoxynucleotide. Lancet 1990; 335: 808–811
   PubMed Web of Science ®Google Scholar
• Calabretta B., Sims R. B., Valtieri M., et al. Normal and Leukemic Hematopoietic Cells Manifest Differential Sensitivity to Inhibitory Effects of c-myb Antisense Oligodeoxynucleotides: An In Vitro Study Relevant to Bone Marrow Purging. Proc. Natl. Acad. Sci. U.S.A. 1991; 88: 2351–2355
   PubMed Web of Science ®Google Scholar
• Wulf G. M., Adra C. N., Lim B. Inhibition of Hematopoietic Development from Embryonic Stem Cells by Antisense vav RNA. EMBO J. 1993; 12: 5065–5074
   PubMed Web of Science ®Google Scholar
• Cotter F. E., Johnson P., Hall P., Pocock C., et al. Antisense Oligonucleotides Suppress B-Cell Lymphoma Growth in a SCID-hu Mouse Model. Oncogene 1994; 9: 3049–3055
   PubMed Web of Science ®Google Scholar
• Gryaznov S., Skorski T., Cucco C., Nieborowska S. M., et al. Oligonucleotide N3′—P5′ Phosphoramidates as Antisense Agents. Nucleic Acids Res. 1996; 24: 1508–1514
   PubMed Web of Science ®Google Scholar
• Gewirtz A. M., Sokol D. L., Ratajczak M. Z. Nucleic Acid Therapies: State of the Art and Future Prospects. Blood 1998; 92: 712–736
   PubMed Web of Science ®Google Scholar
• Ratajczak M. Z., Kant J. A., Luger S. M., et al. In Vivo Treatment of Human Leukemia in a scid Mouse Model with c-myb Antisense Oligodeoxynucleotides. Proc. Natl. Acad. Sci. U.S.A. 1992; 89: 11823–11827
   PubMed Web of Science ®Google Scholar
• Skorski T., Nieborowska S. M., Wlodarski P., et al. Antisense Oligodeoxynucleotide Combination Therapy of Primary Chronic Myelogenous Leukemia Blast Crisis in SCID Mice. Blood 1996; 88: 1005–1012
   PubMed Web of Science ®Google Scholar
• de Fabritiis P., Amadori S., Petti M. C., et al. In Vitro Purging with BCR-ABL Antisense Oligodeoxynucleotides Does Not Prevent Haematologic Reconstitution After Autologous Bone Marrow Transplantation. Leukemia 1995; 9: 662–664
   PubMed Web of Science ®Google Scholar
• Bishop M. R., Iversen P. L., Bayever E., et al. Phase I Trial of an Antisense Oligonucleotide OL(1)p53 in Hematologic Malignancies. J. Clin. Oncol. 1996; 14: 1320–1326
   PubMed Web of Science ®Google Scholar
• Gewirtz A. M., Luger S. M., Stadtmauer E. Bone Marrow Purging with Oligodeoxynucleotides. Blood 1996; 88: 1517
   PubMed Web of Science ®Google Scholar
• Webb A., Cunningham D., Cotter F., et al. BCL-2 Antisense Therapy in Patients with Non-Hodgkin Lymphoma. Lancet 1997; 349: 1137–1141
   PubMed Web of Science ®Google Scholar
• O'Dwyer P. J., Stevenson J. P., Gallagher M., et al. craf-1 Depletion and Tumor Responses in Patients Treated with the c-raf-1 Antisense Oligodeoxynucleotide ISIS 5132 (CGP 69846A). Clin. Cancer Res. 1999; 5: 3977–3982
   PubMed Web of Science ®Google Scholar
• Rossi J. J., Sarver N. Catalytic Antisense RNA (ribozymes): Their Potential and Use as Anti-Hiv-1 Therapeutic Agents. Innovations in Antiviral Development and the Detection of Virus Infection, T. Block. Plenum Press, New York 1992; 95–109
   Google Scholar
• O'Brien S. G., Kirkland M. A., Melo J. V., et al. Antisense BCR-ABL Oligomers Cause Non-Specific Inhibition of Chronic Myeloid Leukemia Cell Lines. Leukemia 1994; 8: 2156–2162
   PubMed Web of Science ®Google Scholar
• Maekawa T., Kimura S., Hirakawa K., et al. Sequence Specificity on the Growth Suppression and Induction of Apoptosis of Chronic Myeloid Leukemia Cells by BCRABL Anti-Sense Oligodeoxynucleoside Phosphorothioates. Int. J. Cancer 1995; 62: 63–69
   PubMed Web of Science ®Google Scholar
• Lieber A., Strauss M. Selection of Efficient Cleavage Sites in Target RNAs by Using a Ribozyme Expression Library. Mol. Cell Biol. 1995; 15: 540–551
   PubMed Web of Science ®Google Scholar
• Sioud M. Effects of Variations in Length of Hammerhead Ribozyme Antisense Arms upon the Cleavage of Longer RNA Substrates. Nucleic Acids Res. 1997; 25: 333–338
   PubMed Web of Science ®Google Scholar
• L'Huillier P. J., Davis S. R., Bellamy A. R. Cytoplasmic Delivery of Ribozymes Leads to Efficient Reduction in αLactalbumin mRNA Levels in C127I Mouse Cells. EMBO J. 1992; 11: 4411–4418
   PubMed Web of Science ®Google Scholar
• De Young M., Kincade D. J., Boehm C. A. Functional Characterization of Ribozymes Expressed Using U1 and T7 Vectors for the Intracellular Cleavage of ANF mRNA. Biochemistry 1994; 33: 12127–12138
   PubMed Web of Science ®Google Scholar
• Jarvis T. C., Wincott F. E., Alby L. J., et al. Optimising the Cell Efficacy of Synthetic Ribozymes. Site Selection and Chemical Modifications of Ribozymes Targeting the Proto-Oncogene c-myb. J. Biol. Chem. 1996; 271: 29107–29112
   PubMed Web of Science ®Google Scholar
• Campbell T. B., McDonald C. K., Hagan M. The Effect of Structure in a LongTargetRNAonRibozymeCleavage Efficiency. Nucleic Acids Res. 1997; 25: 4985–4993
   PubMed Web of Science ®Google Scholar
• Herschlag D. Implications of Ribozyme Kinetics for Targeting the Cleavage of Specific RNA Molecules In Vivo: More Isn't Always Better. Proc. Natl. Acad. Sci. U.S.A. 1991; 88: 6921–6925
   PubMed Web of Science ®Google Scholar
• Goodchild J., Kohli V. Ribozymes That Cleave an RNA Sequence from Human Immunodeficiency Virus: The Effect of Flanking Sequence on Rate. Arch. Biochem. Biophys. 1991; 284: 386–391
   PubMed Web of Science ®Google Scholar
• Bertrand E., Pictet R., Grange T. Can Hammerhead Ribozymes Be Efficient Tools to Inactivate Gene Function. Nucleic Acids Res. 1994; 22: 293–300
   PubMed Web of Science ®Google Scholar
• Scanlon K. J., Jiao L., Funato T., et al. Ribozyme-Mediated Cleavage of c-fos mRNA Reduces Gene Expression of DNA Synthesis Enzymes and Metallothionein. Proc. Natl. Acad. Sci. U.S.A. 1991; 88: 10591–10595
   PubMed Web of Science ®Google Scholar
• Benedict C. M., Pan W., Loy S. E., et al. Triple Ribozyme-Mediated Down-Regulation of the Retinoblastoma Gene. Carcinogenesis 1998; 19: 1223–1230
   PubMed Web of Science ®Google Scholar
• Tang C. K., Goldstein D. J., Payne J., et al. ErbB-4 Ribozymes Abolish Neuregulin-Induced Mitogenesis. Cancer Res. 1998; 58: 3415–3422
   PubMed Web of Science ®Google Scholar
• Czubayko F., Riegel A. T., Wellstein A. Ribozyme-Targeting Elucidates a Direct Role of Pleiotrophin in Tumor Growth. J. Biol. Chem. 1994; 269: 21358–21363
   PubMed Web of Science ®Google Scholar
• Larsson S., Hotchkiss G., Andang M., et al. Reduced β2-Microglobulin mRNA Levels in Transgenic Mice Expressing a Designed Hammerhead Ribozyme. Nucleic Acids Res 1994; 22: 2242–2248
   PubMed Web of Science ®Google Scholar
• Mahieu M., Deschuyteneer R., Forget D., et al. Construction of a Ribozyme Directed Against Human Interleukin- 6 mRNA: Evaluation of Its Catalytic Activity In Vitro and In Vivo. Blood 1994; 84: 3758–3765
   PubMed Web of Science ®Google Scholar
• Maelandsmo G. M., Houig E., Skrede M., et al. Reversal of the In Vivo Metastatic Phenotype of Human Tumor Cells by an Anti-CAPL (mts1) Ribozyme. Cancer Res. 1996; 56: 5490–5498
   PubMed Web of Science ®Google Scholar
• Yamazaki H., Kijima H., Ohnishi Y., et al. Inhibition of Tumor Growth by Ribozyme-Mediated Suppression of Aberrant Epidermal Growth Factor Receptor Gene Expression. J. Natl. Cancer Inst. 1998; 90: 581–587
   PubMed Web of Science ®Google Scholar
• Weerasinghe M., Liem S., Asad S., et al. Resistance to Human Immunodeficiency Virus Type 1 (HIV-1) Infection in Human CD4− Lymphocyte-Derived Cell Lines Conferred by Using Retroviral Vectors Expressing an HIV-1 RNA-Specific Ribozyme. J. Virol. 1991; 65: 5531–5534
   PubMed Web of Science ®Google Scholar
• Cai D. W., Mukhopadhyay T., Roth J. A. Suppression of Lung Cancer Cell Growth by Ribozyme-Mediated Modification of p53 Pre-mRNA. Cancer Gene Ther 1995; 2: 199–205
   PubMed Web of Science ®Google Scholar
• Bauer G., Valdez P., Kearns K., et al. Inhibition of Human Immunodeficiency Virus-1 (HIV-1) Replication After Transduction of Granulocyte Colony-Stimulating Factor-Mobilised CD34− Cells from HIV-1-Infected Donors Using Retroviral Vectors Containing Anti-HIV-1 Genes. Blood 1997; 89: 2259–2267
   PubMed Web of Science ®Google Scholar
• Li M., Lionel H., Citarella R., et al. Tumor Inhibitory Activity of Anti-Ras Ribozymes Delivered by Retroviral Gene Transfer. Cancer Gene Ther. 1996; 3: 221–229
   PubMed Web of Science ®Google Scholar
• Etkin M., Filaccio M., Ellerson D., et al. Use of Cell-Free Retroviral Vector Preparations for Transduction of Cells from the Marrow of Chronic Phase and Blast Crisis Chronic Myelogenous Leukemia Patients and from Normal Individuals. Hum. Gene Ther. 1992; 3: 137–145
   PubMed Web of Science ®Google Scholar
• Blaese M., Blankenstein T., Brenner M., et al. Vectors in Cancer Therapy: How Will They Deliver. Cancer Gene Ther. 1995; 2: 291–297
   PubMed Web of Science ®Google Scholar
• Rossi J. J. Controlled, Targeted, Intracellular Expression of Ribozymes: Progress and Problems. Trends Biotechnol 1995; 13: 301–306
   PubMed Web of Science ®Google Scholar
• Naldini L., Blomer U., Gallay P., et al. In Vivo Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector. Science 1996; 272: 263–267
   PubMed Web of Science ®Google Scholar
• Poeschla E. M., Wong-Staal F., Looney D. J. Efficient Transduction of Nondividing Human Cells by Feline Immunodeficiency Virus Lentiviral Vectors. Nature Med. 1998; 4: 354–357
   PubMed Web of Science ®Google Scholar
• Feng M., Cabrera G., Deshane J., et al. Neoplastic Reversion Accomplished by High Efficiency Adenoviral-Mediated Delivery of an Anti-Ras Ribozyme. Cancer Res. 1995; 55: 2024–2028
   PubMed Web of Science ®Google Scholar
• Lieber A., Kay M. A. Adenovirus-Mediated Expression of Ribozymes in Mice. J. Virol 1996; 70: 3153–3158
   PubMed Web of Science ®Google Scholar
• Czubayko F., Downing S. G., Hsieh S. S., et al. Adenovirus-Mediated Transduction of Ribozymes Abrogates HER-2/neu and Pleiotrophin Expression and Inhibits Tumor Cell Proliferation. Gene Ther. 1997; 4: 943–949
   PubMed Web of Science ®Google Scholar
• Berkner K. L. Development of Adenovirus Vectors for the Expression of Heterologous Genes. Biotechniques 1988; 6: 616–629
   PubMed Web of Science ®Google Scholar
• Smith S. M., Maldarelli F., Jeang K-T. Efficient Expression by an Alphavirus Replicon of a Functional Ribozyme Targeted to Human Immunodeficiency Virus Type I. J. Virol 1997; 71: 9713–9721
   PubMed Web of Science ®Google Scholar
• Sioud M., Natvig J., Forre O. Preformed Ribozyme Destroys Tumour Necrosis Factor mRNA in Human Cells. J. Mol. Biol. 1992; 223: 831–835
   PubMed Web of Science ®Google Scholar
• Kiehntopf M., Brach M. A., Licht T., et al. Ribozyme-Mediated Cleavage of the MDR-1 Transcript Restores Chemosensitivity in Previously Resistant Cancer Cells. EMBO J. 1994; 13: 4645–4652
   PubMed Web of Science ®Google Scholar
• Matsushita H., Kizaki M., Kobayashi H., et al. Induction of Apoptosis in Myeloid Leukaemic Cells by Ribozymes Targeted Against AML1/MTG8. Br. J. Cancer 1999; 79: 1325–1331
   PubMed Web of Science ®Google Scholar
• Czubayko F., Schulte A. M., Bercham G. J., et al. Melanoma Angiogenesis and Metastasis Modulated by Ribozyme Targeting of the Secreted Growth Factor Pleiotrophin. Proc. Natl. Acad. Sci. U.S.A. 1996; 93: 14753–14758
   PubMed Web of Science ®Google Scholar
• Juhl H., Downing S. G., Wellsrein A., et al. HER-2/neu is Rate-Limiting for Ovarian Cancer Growth. J. Biol. Chem. 1997; 272: 29482–29486
   PubMed Web of Science ®Google Scholar
• Iversen P. O., Sioud M. Modulation of Granulocyte-Macrophage Colony-Stimulating Factor Gene Expression by a Tumor Necrosis Factor-Specific Ribozyme in Juvenile Myelomonocytic Leukemic Cells. Blood 1998; 92: 4263–4268
   PubMed Web of Science ®Google Scholar
• Ke L. D., Fueyo J., Chen X., et al. A Novel Approach to Glioma Gene Therapy: Downregulation of the Vascular Endothelial Growth Factor in Glioma Cells Using Ribozymes. Int. J. Oncol 1998; 12: 1391–1396
   PubMed Web of Science ®Google Scholar
• Tsuchida T., Kijima H., Oshika Y., et al. Hammerhead Ribozyme Specifically Inhibits Mutant K-ras mRNA of Human Pancreatic Cancer Cells. Biochem. Biophys. Res. Commun. 1998; 253: 368–373
   Google Scholar
• Yokoyama Y., Morishita S., Takahashi Y., et al. Modulation of c-fms Proto-Oncogene in an Ovarian Carci- 508 Wright and Kearney noma Cell Line by a Hammerhead Ribozyme. Br. J. Cancer 1997; 76: 977–982
   PubMed Web of Science ®Google Scholar
• Konopka K., Rossi J., Swiderski P., et al. Delivery of an Anti-HIV-1 Ribozyme into HIV-Infected Cells Via Cationic Liposomes. Biochim. Biophys. Acta 1998; 1372: 55–68
   PubMed Web of Science ®Google Scholar
• Flory C. M., Pavco P. A., Jarvis T. C., et al. Nuclease-Resistant Ribozymes Decrease Stromelysin mRNA Levels in Rabbit Synovium Following Exogenous Delivery to the Knee Joint. Proc. Natl. Acad. Sci. U.S.A. 1996; 93: 754–758
   PubMed Web of Science ®Google Scholar
• Cotton M., Schaffner G., Birnsteil M. L. Ribozyme, Antisense RNA, and Antisense DNA Inhibition of U7 Small Nuclear Ribonucleoprotein-Mediated Histone Pre-mRNA Processing In Vitro. Mol. Cell Biol. 1989; 9: 4479–4487
   PubMed Web of Science ®Google Scholar
• Yuyama N., Ohkawa J., Inokuchi Y., et al. Construction of a tRNA-Embedded-Ribozyme Trimming Plasmid. Biochem. Biophys. Res. Commun. 1992; 186: 1271–1279
   PubMed Web of Science ®Google Scholar
• Kiehntopf M., Esquivel E. L., Brach M. A., et al. Ribozymes: Biology, Biochemistry, and Implications for Clinical Medicine. J. Mol. Med. 1995; 73: 65–71
   PubMed Web of Science ®Google Scholar
• Bertrand E. L., Castanotto D., Zhou C., et al. The Expression Cassette Determines the Functional Activity of Ribozymes in Mammalian Cells by Controlling Their Intracellular Localization. RNA 1997; 3: 75–88
   PubMedGoogle Scholar
• Heidenreich O., Benseler F., Fahrenholz A., et al. High Activity and Stability of Hammerhead Ribozymes Containing 2′-Modified Pyrimidine Nucleosides and Phosphorothioates. J. Biol. Chem. 1994; 269: 2131–2138
   PubMed Web of Science ®Google Scholar
• Gu J. L., Veerapanane D., Rossi J., et al. Ribozyme-Mediated Inhibition of Expression of Leukocyte-Type 12-Lipoxygenase in Porcine Aortic Vascular Smooth Muscle Cells. Circ. Res. 1995; 77: 14–20
   PubMed Web of Science ®Google Scholar
• Snyder D. S., Wu Y., McMahon R., et al. Ribozyme-Mediated Inhibition of a Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Cell Line Expressing the p190 bcr-abl Oncogene. Biol. Blood Bone Marrow Transplant 1997; 3: 179–186
   PubMedGoogle Scholar
• Taylor N. R., Kaplan B. E., Swiderski P., et al. Chimeric DNA-RNA Hammerhead Ribozymes Have Enhanced In Vitro Catalytic Efficiency and Increased Stability In Vivo. Nucleic Acids Res. 1992; 20: 4559–4565
   PubMed Web of Science ®Google Scholar
• Sioud M., Opstad A., Hendry P., et al. A Minimised Hammerhead Ribozyme with Activity Against Interleukin- 2 in Human Cells. Biochem. Biophys. Res. Commun. 1997; 231: 397–402
   PubMed Web of Science ®Google Scholar
• Kuwabara T., Warashina M., Tanabe T., et al. Comparison of the Specificities and Catalytic Activities of Hammerhead Ribozymes and DNA Enzymes with Respect to the Cleavage of BCR-ABL Chimeric L6 (b2a2) mRNA. Nucleic Acids Res. 1997; 25: 3074–3081
   PubMed Web of Science ®Google Scholar
• Santoro S. W., Joyce G. F. A General Purpose RNACleaving DNA Enzyme. Proc. Natl. Acad. Sci. U.S.A. 1997; 94: 4262–4266
   PubMed Web of Science ®Google Scholar
• Pieken W. A., Olsen D. B., Benseler F., et al. Kinetic Characterization of Ribonuclease-Resistant 2′-Modified Hammerhead Ribozymes. Science 1991; 253: 314–317
   PubMed Web of Science ®Google Scholar
• Paolella G., Sproat B. S., Lamond A. I. Nuclease Resistant Ribozymes with High Catalytic Activity. EMBO J. 1992; 11: 1913–1919
   PubMed Web of Science ®Google Scholar
• Beigelman L., McSwiggen J. A., Draper K. G., et al. Chemical Modification of Hammerhead Ribozymes. Catalytic Activity and Nuclease Resistance. J. Biol. Chem. 1995; 270: 25702–25708
   PubMed Web of Science ®Google Scholar
• Kashani-Sabet M., Scanlon K. J. Application of Ribozymes to Cancer Gene Therapy. Cancer Gene Ther. 1995; 2: 213–223
   PubMed Web of Science ®Google Scholar
• L'Huillier P. J., Soulier S., Stinnakre M. G., et al. Efficient and Specific Ribozyme-Mediated Reduction of Bovine α-Lactalbumin Expression in Double Transgenic Mice. Proc. Natl. Acad. Sci. U.S.A. 1996; 93: 6698–6703
   PubMed Web of Science ®Google Scholar
• Scanlon K. J., Ishida H., Kashani-Sabet M. Ribozyme-Mediated Reversal of the Multidrug-Resistant Phenotype. Proc. Natl. Acad. Sci. U.S.A. 1994; 91: 11123–11127
   PubMed Web of Science ®Google Scholar
• Wright L. A., Milliken S., Biggs J. C., et al. In Vivo Effects Associated with the Expression of a bcr-abl Specific Ribozyme in a CML Cell Line. Antisense Nucleic Acid Drug Dev. 1998; 8: 15–23
   PubMedGoogle Scholar
• Denman R. B., Smedman M., Ju W., et al. Ribozyme Mediated Degradation of β-Amyloid Peptide Precursor mRNA in COS-7 Cells. Nucleic Acids Res. 1994; 22: 2375–2382
   PubMed Web of Science ®Google Scholar
• Efrat S., Leiser M., Wu Y. J., et al. Ribozyme-Mediated Attenuation of Pancreatic β-Cell Glucokinase Expression in Transgenic Mice Results in Impaired Glucose-Induced Insulin Secretion. Proc. Natl. Acad. Sci. U.S.A. 1994; 91: 2051–2055
   PubMed Web of Science ®Google Scholar
• Ohta Y., Kijima H., Ohkawa T., et al. Tissue-Specific Expression of an Anti-ras Ribozyme Inhibits Proliferation of Human Malignant Melanoma Cells. Nucleic Acids Res 1996; 24: 938–942
   PubMed Web of Science ®Google Scholar
• Irminger-Finger I., Soriano J., Vaudan G., et al. In Vitro Repression of Brca1-Associated RING Domain Gene, Bard1, Induces Phenotypic Changes in Mammary Epithelial Cells. J. Cell Biol. 1998; 143: 1329–1339
   PubMed Web of Science ®Google Scholar
• Tang X. B., Hobom G., Luo D. Ribozyme Mediated Destruction of Influenza A Virus In Vitro and In Vivo. J. Med. Virol 1994; 42: 385–395
   PubMed Web of Science ®Google Scholar
• Thompson J. D., Ayers D. F., Malmstrom T. A., et al. Improved Accumulation and Activity of Ribozymes Expressed from a tRNA-Based RNA Polymerase III Promoter. Nucleic Acids Res. 1995; 23: 2259–2268
   PubMed Web of Science ®Google Scholar
• Wiechen K., Zimmer C., Dietel M. Selection of a High Activity c-erbB-2 Ribozyme Using a Fusion Gene of c-erbB-2 and the Enhanced Green Fluorescent Protein. Cancer Gene Ther. 1998; 5: 45–51
   PubMed Web of Science ®Google Scholar
• Gunning P., Leavitt J., Muscat G., et al. A Human β-Actin Expression Vector System Directs High-Level Accumulation of Antisense Transcripts. Proc. Natl. Acad. Sci. U.S.A. 1987; 84: 4831–4835
   PubMed Web of Science ®Google Scholar
• Yokoyama Y., Takahashi Y., Shinohara A., et al. Attenuation of Telomerase Activity by a Hammerhead Ribozyme Targeting the Template Region of Telomerase RNA in Endometrial Carcinoma Cells. Cancer Res. 1998; 58: 5406–5410
   PubMed Web of Science ®Google Scholar
• Kashani-Sabet M., Funato T., Florenes V. A., et al. Suppression of the Neoplastic Phenotype In Vivo by an Anti-ras Ribozyme. Cancer Res. 1994; 54: 900–902
   PubMed Web of Science ®Google Scholar
• Ding D., Lipshitz H. D. Localized RNAs and Their Functions. Bioessays 1993; 15: 651–658
   PubMed Web of Science ®Google Scholar
• Sullenger B. A. Colocalizing Ribozymes with Substrate RNAs to Increase Their Efficacy as Gene Inhibitors. Appl. Biochem. Biotechnol 1995; 54: 57–61
   PubMed Web of Science ®Google Scholar
• Sullenger B. A., Cech T. Tethering Ribozymes to a Retroviral Packaging Signal for Destruction of Viral RNA. Science 1993; 262: 1566–1569
   PubMed Web of Science ®Google Scholar
• Kislauskis E. H., Li Z., Singer R. H., et al. Isoform- Specific 3′-Untranslated Sequences Sort Alpha-Cardiac and Beta-Cytoplasmic Actin Messenger RNAs to Different Cytoplasmic Compartments. J. Cell Biol. 1993; 123: 165–172
   PubMed Web of Science ®Google Scholar
• Nowell P. C., Hungerford D. AMinute Chromosome in Human Chronic Granulocytic Leukemia. Science 1960; 132: 1497–1501
   Web of Science ®Google Scholar
• Shtivelman E., Lifshitz B., Gale R. P., et al. Fused Transcript of abl and bcr Genes in Chronic Myelogenous Leukaemia. Nature 1985; 315: 550–554
   PubMed Web of Science ®Google Scholar
• Daley G. Q., Ben-Neriah Y. Implicating the bcr/abl Gene in the Pathogenesis of Philadelphia Chromosome- Positive Human Leukemia. Adv. Cancer Res. 1991; 57: 151–184
   PubMed Web of Science ®Google Scholar
• Lange W., Cantin E. M., Finke J., et al. In Vitro and In Vivo Effects of Synthetic Ribozymes Targeted Against BCR/ABL mRNA. Leukemia 1993; 7: 1786–1794
   PubMed Web of Science ®Google Scholar
• Leopold L. H., Shore S., Newkirk T. A., et al. Multi- Unit Ribozyme-Mediated Cleavage of bcr-abl mRNA in Myeloid Leukemias. Blood 1995; 85: 2162–2170
   PubMed Web of Science ®Google Scholar
• Snyder D. S., Wu Y., Wang J. L., et al. Ribozyme-Mediated Inhibition of bcr-abl Gene Expression in a Philadelphia Chromosome-Positive Cell Line. Blood 1993; 82: 600–605
   PubMed Web of Science ®Google Scholar
• Shore S. K., Nabissa P. M., Reddy E. P., et al. Ribozyme Mediated Cleavage of the BCRABL Oncogene Transcript: In Vitro Cleavage of RNA and In Vivo Loss of P210 Protein-Kinase Activity. Oncogene 1993; 8: 3183–3188
   PubMed Web of Science ®Google Scholar
• Wright L., Wilson S., Milliken S., et al. Ribozyme- Mediated Cleavage of the bcr/abl Transcript Expressed in Chronic Myeloid Leukaemia. Exp. Hematol 1993; 21: 1714–1718
   Web of Science ®Google Scholar
• Kearney P., Wright L., Milliken S., et al. Improved Specificity of Ribozyme-Mediated Cleavage of bcr-abl mRNA. Exp. Hematol 1995; 23: 986–989
   Web of Science ®Google Scholar
• Bos J. L. Ras Oncogenes in Human Cancer:. A Review. Cancer Res. 1989; 49: 4682–4689
   PubMed Web of Science ®Google Scholar
• Scherr M., Maurer A. B., Klein S., et al. Effective Reversal of a Transformed Phenotype by Retrovirus- Mediated Transfer of a Ribozyme Directed Against Mutant N-ras. Gene Ther. 1998; 5: 1227–1234
   PubMed Web of Science ®Google Scholar
• Dorai T., Olsson C. A., Katz A. E., et al. Development of a Hammerhead Ribozyme Against bcl-2. I. Preliminary Evaluation of a Potential Gene Therapeutic Agent for Hormone-Refractory Human Prostate Cancer. Prostate 1997; 32: 246–258
   PubMed Web of Science ®Google Scholar
• Dorai T., Goluboff E. T., Olsson C. A., et al. Development of a Hammerhead Ribozyme Against BCL-2. II. Ribozyme Treatment Sensitizes Hormone-Resistant Prostate Cancer Cells to Apoptotic Agents. Anticancer Res. 1997; 17: 3307–3312
   PubMed Web of Science ®Google Scholar
• Nason-Burchenal K., Allopenna J., Begue A., et al. Targeting of PML/RARalpha is Lethal to Retinoic Acid-Resistant Promyelocytic Leukemia Cells. Blood 1998; 92: 1758–1767
   PubMed Web of Science ®Google Scholar
• Xu Z. D., Oey L., Mohan S., et al. Hammerhead Ribozyme- Mediated Cleavage of the Human Insulin-Like Growth Factor-II Ribonucleic Acid In Vitro and in Prostate Cancer Cells. Endocrinology 1999; 140: 2134–2144
   PubMed Web of Science ®Google Scholar
• Chen S., Song C. S., Lavrovsky Y., et al. Catalytic Cleavage of the Androgen Receptor Messenger RNA and Functional Inhibition of Androgen Receptor Activity by a Hammerhead Ribozyme. Mol. Endocrinol 1998; 12: 1558–1566
   PubMed Web of Science ®Google Scholar
• Rowe P. M. Ribozymes Enter Clinical Trials for HIV- 1 Treatment. Lancet 1996; 348: 1302
   PubMed Web of Science ®Google Scholar
• Kozu T., Sueoka E., Okabe S., et al. Designing of Chimeric DNA/RNA Hammerhead Ribozymes to be Targeted Against AML1/MTG8 mRNA. J. Cancer Res. Clin. Oncol. 1996; 122: 254–256
   PubMed Web of Science ®Google Scholar
• Sato K., Nishi T., Takeshima H., et al. Expression of p120 Nucleolar Proliferating Antigen in Human Gliomas and Growth Suppression of Glioma Cells by p120 Ribozyme Vector. Int. J. Oncol. 1999; 14: 417–424
   PubMed Web of Science ®Google Scholar
• Dorai T., Kobayashi H., Holland J. F., et al. Modulation of Platelet-Derived Growth Factor-β mRNA Expression and Cell Growth in a Human Mesothelioma Cell Line by a Hammerhead Ribozyme. Mol. Pharmacol 1994; 46: 437–444
   PubMed Web of Science ®Google Scholar
• Kanazawa Y., Ohkawa K., Ueda K., et al. Hammerhead Ribozyme-Mediated Inhibition of Telomerase Activity in Extracts of Human Hepatocellular Carcinoma Cells. Biochem. Biophys. Res. Commun. 1996; 225: 570–576
   PubMed Web of Science ®Google Scholar